Tag Archives: Exiqon
Long non-coding RNAs in the cardiovascular system
What is the background for your current project involving LNA™ GapmeRs? Endothelial cells control pivotal functions of the cardiovascular system. We hypothesized that lncRNAs are important for endothelial cell function and performed next generation sequencing experiments with human endothelial cells to identify lncRNAs that are present in endothelial cells.
Exiqon Announces 2014 Grant Program for microRNA, long non-coding RNA or mRNA research
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the launch of its 2014 global research grant program, open to researchers from academic and non-profit institutions.
“Exiqon aims to support our customers around the world in their everyday laboratory work and we are proud to offer excellent products for the analysis of any RNA in any biological system. With this grant program we intend to provide access to cutting edge technology and enable scientists to take the next critical step in their RNA research”, said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.
The Exiqon Grant Program has been established with an internal seed funding of 3 grants each worth USD 12,500 (EUR 9,000) which will be given to researchers who can best demonstrate how Exiqon can help them accelerate their RNA discoveries.
Recipients will use Exiqon Grant Program awards for the purchase of any of Exiqon’s RNA products or services. Exiqon offers a complete product line for RNA investigation, including products for RNA isolation, microRNA microarray analysis, qPCR analysis, Northern Blotting, In Situ Hybridization and functional analysis studies. Exiqon also offers microRNA profiling services based on Next Generation Sequencing, microarray and qPCR analysis, complete with full sample QC and customized data analysis and reporting.
Researchers are invited to submit an application outlining their research area, project goals and proposed workflow no later than Friday, 31 January 2024. Award conveyance through the Exiqon Grant Program does not influence, and is not influenced by, any other existing or potential sources of project funding.
Applications must be submitted electronically via a special Grant Program webpage http://www.exiqon.com/ls/grants. Grant recipients will be announced early March 2014.
Additional information:
Additional information is available through Exiqon representatives located across North America and Europe. Interested parties are also invited to contact Exiqon at 1-888-647-2879 (U.S.)/ +45 4566 0888 (EU) or using www.exiqon.com/contact.
Exiqon launches qPCR Array product for custom designed microRNA, mRNA and lncRNA assays
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of fully customizable qPCR arrays that allow for simultaneous detection of any microRNA, mRNA and lncRNA.
As more scientists engage in next generation sequencing the need to verify gene expression discovered by sequencing grows. Researchers studying specific developmental or disease pathways are now able to profile microRNA interactions with target mRNA or lncRNA in the same experiment by combining LNA™ primers for microRNA, mRNA and lncRNA in one single qPCR panel.
Incoming search terms:
- lightspeed genomics vp
Webinar - Advances in Gene Silencing - New Tools for knockdown of mRNA and lncRNA
Join this free webinar to learn about:
• | The new advanced tools for potent gene silencing in vitro and in vivo |
• | The challenges of inhibiting long non-coding RNA and how to overcome them |
• | The essentials of a successful RNA knockdown experiment using LNA™ GapmeRs |
Thursday November 14, 2023
Chicago 9:00, Boston 10:00, London 15:00, Berlin 16:00,
Delhi 19:30, Beijing 22:00. The webinar will be available on demand a couple of days after the live event.
Exiqon launches advanced on-line tool for design of LNA gapmers for inhibition of mRNA and lncRNA
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced an extension to the LNA™ longRNA GapmeR product line with the launch of a novel on-line bioinformatics tool for the design of custom LNA™-gapmer antisense oligonucleotides for specific and efficient inhibition of mRNA and lncRNA.
The new on-line LNA™ gapmer design tool allows scientists to effortlessly design optimal LNA™ gapmers through a simple and intuitive interface.
The tool provides a ranked list of LNA™ gapmer designs that takes into account more than 30 design criteria in the evaluation of more than 100,000 different in silico designs which allows the scientist to quickly select preferred designs and product format. The underlying software to the new on-line LNA™ gapmer design tool includes important performance parameters such as LNA spiking pattern, target accessibility, secondary structures and potential off-targets based on searches against several gene databases including ENSEMBL.
The design tool is wet-lab validated with hundreds of LNA™ gapmer antisense oligonucleotides having been tested in cell cultures and in animal models.
New to Exiqon’s LNA™ longRNA GapmeR product offering is a number of carefully selected and wet-lab validated negative control assays.
“The new on-line design tool is perfectly suited for scientists who have identified interesting targets for instance by next generation sequence analysis and would like to understand the functionality of such targets“ says Senior Vice President, Sales & Marketing, Henrik M. Pfundheller and continues “Since the launch of the product line earlier this year we have seen a very rapid adaptation by our customers which I believe is due to the substantial body of scientific literature supporting the superior performance of LNA™ gapmers”.
LNA™ longRNA GapmeRs are high affinity antisense oligonucleotides used for functional analysis that allow researchers to study the gene function and downstream biological implications of silencing a specific mRNA or long non-coding RNA (lncRNA) in cell-cultures or animal models. The unique LNA™-enhanced design of the LNA™ longRNA GapmeR offers superior performance compared to alternative RNA silencing methods including siRNA. Even targets located in the nucleus are effectively silenced by the LNA™ longRNA GapmeRs. The incorporation of LNA™ increases bio-stability which secures the biological activity over an extended period of time and provides excellent pharmacokinetic and pharmacodynamics properties including high stability and low toxicity making them ideal for in vivo testing.
Exiqon offers a range of compatible LNA™ enhanced products for mRNA and lncRNA research including products for qPCR and in situ hybridization analysis.
Information about the LNA™ longRNA GapmeRs is available here: http://www.exiqon.com/gapmers
Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)